The cardiovascular outcome is crucial

Abstract

SGLT2 are transport proteins that reabsorb more than 90% of the glucose excreted by filtration in the kidneys back into the bloodstream. Empagliflozin (Jardiance®) is a selective inhibitor of SGLT2, improving glycemic control in type 2 diabetics with a very low risk of hypoglycaemia. "In addition, the substance also has a beneficial effect on other cardiovascular risk factors," says Prof. Jochen Seufert, Freiburg. Thus, there is a decrease in blood pressure, weight, visceral fat and albuminuria. ...